ID   NFASC_HUMAN             Reviewed;        1347 AA.
AC   O94856; B2RNN8; B3KQZ1; B5MDP6; B5MDR6; B7ZMD8; Q149P5; Q5T2F0; Q5T2F1;
AC   Q5T2F2; Q5T2F3; Q5T2F4; Q5T2F5; Q5T2F6; Q5T2F7; Q5T2F9; Q5T2G0; Q5W9F8;
AC   Q68DH3; Q6ZQV6; Q7Z3K1; Q96HT1; Q96K50;
DT   14-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   06-DEC-2005, sequence version 4.
DT   28-JUN-2023, entry version 197.
DE   RecName: Full=Neurofascin;
DE   Flags: Precursor;
GN   Name=NFASC; Synonyms=KIAA0756;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=9872452; DOI=10.1093/dnares/5.5.277;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A.,
RA   Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XI. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 5:277-286(1998).
RN   [2]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 804-1347 (ISOFORMS 3/4), NUCLEOTIDE SEQUENCE [LARGE
RP   SCALE MRNA] OF 931-1347 (ISOFORM 6), AND NUCLEOTIDE SEQUENCE [LARGE SCALE
RP   MRNA] OF 972-1347 (ISOFORM 1).
RC   TISSUE=Teratocarcinoma, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 9), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 326-1347 (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 193-1347 (ISOFORM 5).
RX   PubMed=15491607; DOI=10.1016/j.jmb.2004.09.028;
RA   Homma K., Kikuno R.F., Nagase T., Ohara O., Nishikawa K.;
RT   "Alternative splice variants encoding unstable protein domains exist in the
RT   human brain.";
RL   J. Mol. Biol. 343:1207-1220(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1040-1347 (ISOFORM 7), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1204-1347 (ISOFORMS 1/3/4/6/7).
RC   TISSUE=Amygdala, and Esophageal carcinoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-481 AND SER-485, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   INTERACTION WITH MYOC.
RX   PubMed=23897819; DOI=10.1074/jbc.m112.446138;
RA   Kwon H.S., Johnson T.V., Joe M.K., Abu-Asab M., Zhang J., Chan C.C.,
RA   Tomarev S.I.;
RT   "Myocilin mediates myelination in the peripheral nervous system through
RT   ErbB2/3 signaling.";
RL   J. Biol. Chem. 288:26357-26371(2013).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 25-428, GLYCOSYLATION AT ASN-409,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=21047790; DOI=10.1074/jbc.m110.180281;
RA   Liu H., Focia P.J., He X.;
RT   "Homophilic adhesion mechanism of neurofascin, a member of the L1 family of
RT   neural cell adhesion molecules.";
RL   J. Biol. Chem. 286:797-805(2011).
RN   [11]
RP   INVOLVEMENT IN NEDCPMD, AND VARIANT NEDCPMD PRO-359.
RX   PubMed=28940097; DOI=10.1007/s00439-017-1843-2;
RA   Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A.,
RA   Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M.,
RA   Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A.,
RA   Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S.,
RA   Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T.,
RA   Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C.,
RA   Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M.,
RA   Lashley T., Houlden H., Faqeih E., Alkuraya F.S.;
RT   "Expanding the genetic heterogeneity of intellectual disability.";
RL   Hum. Genet. 136:1419-1429(2017).
RN   [12]
RP   ERRATUM OF PUBMED:28940097.
RX   PubMed=29288388; DOI=10.1007/s00439-017-1859-7;
RA   Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A.,
RA   Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M.,
RA   Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A.,
RA   Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S.,
RA   Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T.,
RA   Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C.,
RA   Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M.,
RA   Lashley T., Houlden H., Faqeih E., Alkuraya F.S.;
RT   "Correction to: Expanding the genetic heterogeneity of intellectual
RT   disability.";
RL   Hum. Genet. 137:105-109(2018).
RN   [13]
RP   VARIANT NEDCPMD 835-VAL--ALA-1347 DEL, CHARACTERIZATION OF VARIANT NEDCPMD
RP   835-ARG--ALA-1347 DEL, AND SUBCELLULAR LOCATION (ISOFORM 8).
RX   PubMed=30124836; DOI=10.1093/hmg/ddy277;
RA   Smigiel R., Sherman D.L., Rydzanicz M., Walczak A., Mikolajkow D.,
RA   Krolak-Olejnik B., Kosinska J., Gasperowicz P., Biernacka A., Stawinski P.,
RA   Marciniak M., Andrzejewski W., Boczar M., Krajewski P., Sasiadek M.M.,
RA   Brophy P.J., Ploski R.;
RT   "Homozygous mutation in the Neurofascin gene affecting the glial isoform of
RT   Neurofascin causes severe neurodevelopment disorder with hypotonia, amimia
RT   and areflexia.";
RL   Hum. Mol. Genet. 27:3669-3674(2018).
RN   [14]
RP   INVOLVEMENT IN NEDCPMD, VARIANT NEDCPMD GLU-1229, CHARACTERIZATION OF
RP   VARIANT NEDCPMD GLU-1229, AND SUBCELLULAR LOCATION.
RX   PubMed=30850329; DOI=10.1016/j.parkreldis.2019.02.045;
RA   Monfrini E., Straniero L., Bonato S., Monzio Compagnoni G., Bordoni A.,
RA   Dilena R., Rinchetti P., Silipigni R., Ronchi D., Corti S., Comi G.P.,
RA   Bresolin N., Duga S., Di Fonzo A.;
RT   "Neurofascin (NFASC) gene mutation causes autosomal recessive ataxia with
RT   demyelinating neuropathy.";
RL   Parkinsonism Relat. Disord. 63:66-72(2019).
CC   -!- FUNCTION: Cell adhesion, ankyrin-binding protein which may be involved
CC       in neurite extension, axonal guidance, synaptogenesis, myelination and
CC       neuron-glial cell interactions. {ECO:0000250}.
CC   -!- SUBUNIT: Horseshoe-shaped homodimer. Probable constituent of a
CC       NFASC/NRCAM/ankyrin-G complex. Associates with the sodium channel beta-
CC       1 (SCN1B) and beta-3 (SCN3B) subunits. Interacts with GLDN/gliomedin
CC       (By similarity). Interacts with MYOC. {ECO:0000250,
CC       ECO:0000269|PubMed:21047790, ECO:0000269|PubMed:23897819}.
CC   -!- INTERACTION:
CC       O94856-3; Q8IZP0-5: ABI1; NbExp=3; IntAct=EBI-12035911, EBI-11743294;
CC       O94856-3; Q9NYB9-2: ABI2; NbExp=3; IntAct=EBI-12035911, EBI-11096309;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:30850329};
CC       Single-pass type I membrane protein {ECO:0000255}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 8]: Cell junction, paranodal septate
CC       junction {ECO:0000269|PubMed:30124836}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=13;
CC       Name=1;
CC         IsoId=O94856-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O94856-2; Sequence=VSP_016426, VSP_008938;
CC       Name=3;
CC         IsoId=O94856-3; Sequence=VSP_016424, VSP_016425, VSP_008937,
CC                                  VSP_008940;
CC       Name=4;
CC         IsoId=O94856-4; Sequence=VSP_016427, VSP_016428, VSP_008940;
CC       Name=5;
CC         IsoId=O94856-5; Sequence=VSP_008937, VSP_016429;
CC       Name=6;
CC         IsoId=O94856-6; Sequence=VSP_016430, VSP_016434;
CC       Name=7;
CC         IsoId=O94856-7; Sequence=VSP_016433;
CC       Name=8; Synonyms=Nfasc155 {ECO:0000303|PubMed:30124836};
CC         IsoId=O94856-8; Sequence=VSP_016424, VSP_016425, VSP_008937,
CC                                  VSP_016432;
CC       Name=9;
CC         IsoId=O94856-9; Sequence=VSP_016427, VSP_016428;
CC       Name=10;
CC         IsoId=O94856-10; Sequence=VSP_016424, VSP_008937, VSP_016432;
CC       Name=11;
CC         IsoId=O94856-11; Sequence=VSP_016424, VSP_016425, VSP_016432;
CC       Name=12;
CC         IsoId=O94856-12; Sequence=VSP_016427, VSP_016428, VSP_016432;
CC       Name=13;
CC         IsoId=O94856-13; Sequence=VSP_016431;
CC   -!- DOMAIN: Homophilic adhesion is primarily mediated by the interaction of
CC       the second Ig-like domains.
CC   -!- DISEASE: Neurodevelopmental disorder with central and peripheral motor
CC       dysfunction (NEDCPMD) [MIM:618356]: An autosomal recessive
CC       neurodevelopmental disorder with early onset and a highly variable
CC       phenotype. Disease features include hypotonia apparent from birth, poor
CC       feeding, global developmental delay with absence of reaction to touch
CC       and no eye contact, infantile-onset progressive ataxia and
CC       demyelinating peripheral neuropathy. {ECO:0000269|PubMed:28940097,
CC       ECO:0000269|PubMed:30124836, ECO:0000269|PubMed:30850329}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be due to intron retention.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: May be due to intron retention.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the immunoglobulin superfamily.
CC       L1/neurofascin/NgCAM family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA34476.3; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAB55195.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAC87577.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB018299; BAA34476.3; ALT_INIT; mRNA.
DR   EMBL; AK027553; BAB55195.1; ALT_INIT; mRNA.
DR   EMBL; AK090639; BAG52203.1; -; mRNA.
DR   EMBL; AK127424; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK128699; BAC87577.1; ALT_INIT; mRNA.
DR   EMBL; AC096675; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL391822; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC008124; AAH08124.2; -; mRNA.
DR   EMBL; BC117674; AAI17675.2; -; mRNA.
DR   EMBL; BC137013; AAI37014.1; -; mRNA.
DR   EMBL; BC144454; AAI44455.1; -; mRNA.
DR   EMBL; AB177861; BAD66839.1; -; mRNA.
DR   EMBL; BX537841; CAD97852.1; -; mRNA.
DR   EMBL; CR749402; CAH18247.1; -; mRNA.
DR   CCDS; CCDS30982.1; -. [O94856-3]
DR   CCDS; CCDS53460.1; -. [O94856-9]
DR   CCDS; CCDS53461.1; -. [O94856-2]
DR   CCDS; CCDS53462.1; -. [O94856-8]
DR   CCDS; CCDS91149.1; -. [O94856-11]
DR   RefSeq; NP_001005388.2; NM_001005388.2. [O94856-9]
DR   RefSeq; NP_001005389.2; NM_001005389.1. [O94856-2]
DR   RefSeq; NP_001153803.1; NM_001160331.1. [O94856-11]
DR   RefSeq; NP_001153804.1; NM_001160332.1. [O94856-8]
DR   RefSeq; NP_001153805.1; NM_001160333.1.
DR   RefSeq; NP_055905.2; NM_015090.3. [O94856-3]
DR   RefSeq; XP_011507621.1; XM_011509319.1.
DR   RefSeq; XP_011507630.1; XM_011509328.1.
DR   PDB; 3P3Y; X-ray; 2.60 A; A=25-428.
DR   PDB; 3P40; X-ray; 3.20 A; A=25-428.
DR   PDBsum; 3P3Y; -.
DR   PDBsum; 3P40; -.
DR   AlphaFoldDB; O94856; -.
DR   SMR; O94856; -.
DR   BioGRID; 116737; 6.
DR   IntAct; O94856; 9.
DR   STRING; 9606.ENSP00000344786; -.
DR   CarbonylDB; O94856; -.
DR   GlyConnect; 1552; 15 N-Linked glycans (6 sites).
DR   GlyCosmos; O94856; 9 sites, 15 glycans.
DR   GlyGen; O94856; 12 sites, 15 N-linked glycans (6 sites), 2 O-linked glycans (2 sites).
DR   iPTMnet; O94856; -.
DR   PhosphoSitePlus; O94856; -.
DR   SwissPalm; O94856; -.
DR   BioMuta; NFASC; -.
DR   EPD; O94856; -.
DR   jPOST; O94856; -.
DR   MassIVE; O94856; -.
DR   MaxQB; O94856; -.
DR   PaxDb; O94856; -.
DR   PeptideAtlas; O94856; -.
DR   ProteomicsDB; 50490; -. [O94856-1]
DR   ProteomicsDB; 50491; -. [O94856-10]
DR   ProteomicsDB; 50492; -. [O94856-11]
DR   ProteomicsDB; 50493; -. [O94856-12]
DR   ProteomicsDB; 50494; -. [O94856-13]
DR   ProteomicsDB; 50495; -. [O94856-2]
DR   ProteomicsDB; 50496; -. [O94856-3]
DR   ProteomicsDB; 50497; -. [O94856-4]
DR   ProteomicsDB; 50498; -. [O94856-5]
DR   ProteomicsDB; 50499; -. [O94856-6]
DR   ProteomicsDB; 50500; -. [O94856-7]
DR   ProteomicsDB; 50501; -. [O94856-8]
DR   ProteomicsDB; 50502; -. [O94856-9]
DR   TopDownProteomics; O94856-2; -. [O94856-2]
DR   ABCD; O94856; 1 sequenced antibody.
DR   Antibodypedia; 2194; 249 antibodies from 35 providers.
DR   DNASU; 23114; -.
DR   Ensembl; ENST00000339876.11; ENSP00000344786.6; ENSG00000163531.17. [O94856-9]
DR   Ensembl; ENST00000401399.5; ENSP00000385637.1; ENSG00000163531.17. [O94856-9]
DR   Ensembl; ENST00000403080.5; ENSP00000384875.1; ENSG00000163531.17. [O94856-2]
DR   Ensembl; ENST00000404076.5; ENSP00000385676.1; ENSG00000163531.17. [O94856-10]
DR   Ensembl; ENST00000430393.7; ENSP00000415031.3; ENSG00000163531.17. [O94856-8]
DR   Ensembl; ENST00000513543.6; ENSP00000425908.1; ENSG00000163531.17. [O94856-3]
DR   Ensembl; ENST00000539706.6; ENSP00000438614.2; ENSG00000163531.17. [O94856-11]
DR   GeneID; 23114; -.
DR   KEGG; hsa:23114; -.
DR   MANE-Select; ENST00000339876.11; ENSP00000344786.6; NM_001005388.3; NP_001005388.2. [O94856-9]
DR   UCSC; uc001hbh.4; human. [O94856-1]
DR   AGR; HGNC:29866; -.
DR   CTD; 23114; -.
DR   DisGeNET; 23114; -.
DR   GeneCards; NFASC; -.
DR   HGNC; HGNC:29866; NFASC.
DR   HPA; ENSG00000163531; Tissue enhanced (brain).
DR   MalaCards; NFASC; -.
DR   MIM; 609145; gene.
DR   MIM; 618356; phenotype.
DR   neXtProt; NX_O94856; -.
DR   OpenTargets; ENSG00000163531; -.
DR   PharmGKB; PA128395771; -.
DR   VEuPathDB; HostDB:ENSG00000163531; -.
DR   eggNOG; KOG3513; Eukaryota.
DR   GeneTree; ENSGT00940000157024; -.
DR   HOGENOM; CLU_005756_2_0_1; -.
DR   InParanoid; O94856; -.
DR   OMA; NHSSYPG; -.
DR   OrthoDB; 2912783at2759; -.
DR   PhylomeDB; O94856; -.
DR   TreeFam; TF351098; -.
DR   PathwayCommons; O94856; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-447043; Neurofascin interactions.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; O94856; -.
DR   SIGNOR; O94856; -.
DR   BioGRID-ORCS; 23114; 14 hits in 1147 CRISPR screens.
DR   ChiTaRS; NFASC; human.
DR   EvolutionaryTrace; O94856; -.
DR   GeneWiki; NFASC; -.
DR   GenomeRNAi; 23114; -.
DR   Pharos; O94856; Tbio.
DR   PRO; PR:O94856; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; O94856; protein.
DR   Bgee; ENSG00000163531; Expressed in inferior olivary complex and 185 other tissues.
DR   ExpressionAtlas; O94856; baseline and differential.
DR   Genevisible; O94856; HS.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0043194; C:axon initial segment; ISS:ARUK-UCL.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0101003; C:ficolin-1-rich granule membrane; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0033268; C:node of Ranvier; ISS:BHF-UCL.
DR   GO; GO:0033010; C:paranodal junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0097454; C:Schwann cell microvillus; IEA:Ensembl.
DR   GO; GO:0098632; F:cell-cell adhesion mediator activity; IBA:GO_Central.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0007420; P:brain development; IBA:GO_Central.
DR   GO; GO:0098609; P:cell-cell adhesion; IBA:GO_Central.
DR   GO; GO:0042552; P:myelination; ISS:BHF-UCL.
DR   GO; GO:0007422; P:peripheral nervous system development; ISS:BHF-UCL.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IEA:Ensembl.
DR   CDD; cd00063; FN3; 5.
DR   CDD; cd05731; Ig3_L1-CAM_like; 1.
DR   CDD; cd05845; IgI_2_L1-CAM_like; 1.
DR   CDD; cd05875; IgI_hNeurofascin_like; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 11.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR026966; Neurofascin/L1/NrCAM_C.
DR   InterPro; IPR026965; NFASC_Ig-like.
DR   PANTHER; PTHR44170:SF12; NEUROFASCIN; 1.
DR   PANTHER; PTHR44170; PROTEIN SIDEKICK; 1.
DR   Pfam; PF13882; Bravo_FIGEY; 1.
DR   Pfam; PF00041; fn3; 5.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF13927; Ig_3; 3.
DR   SMART; SM00060; FN3; 5.
DR   SMART; SM00409; IG; 6.
DR   SMART; SM00408; IGc2; 6.
DR   SUPFAM; SSF49265; Fibronectin type III; 3.
DR   SUPFAM; SSF48726; Immunoglobulin; 6.
DR   PROSITE; PS50853; FN3; 5.
DR   PROSITE; PS50835; IG_LIKE; 6.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Cell junction;
KW   Cell membrane; Disease variant; Disulfide bond; Glycoprotein;
KW   Immunoglobulin domain; Membrane; Phosphoprotein; Reference proteome;
KW   Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000255"
FT   CHAIN           25..1347
FT                   /note="Neurofascin"
FT                   /id="PRO_0000015049"
FT   TOPO_DOM        25..1217
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1218..1238
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1239..1347
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          41..137
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          143..230
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          244..332
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          337..424
FT                   /note="Ig-like C2-type 4"
FT   DOMAIN          429..517
FT                   /note="Ig-like C2-type 5"
FT   DOMAIN          521..603
FT                   /note="Ig-like C2-type 6"
FT   DOMAIN          630..725
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          730..823
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          828..930
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          934..1030
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1114..1206
FT                   /note="Fibronectin type-III 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   REGION          713..740
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          915..934
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1011..1040
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1090..1111
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1248..1347
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1248..1272
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1274..1295
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1318..1332
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1333..1347
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         481
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         485
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1267
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q810U3"
FT   MOD_RES         1281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97685"
FT   MOD_RES         1294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97685"
FT   MOD_RES         1297
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97685"
FT   MOD_RES         1333
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q810U3"
FT   MOD_RES         1334
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q810U3"
FT   MOD_RES         1338
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q810U3"
FT   CARBOHYD        305
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        409
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21047790"
FT   CARBOHYD        446
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        483
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        752
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        778
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        973
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        988
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        63..118
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21047790"
FT   DISULFID        162..213
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21047790"
FT   DISULFID        268..316
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21047790"
FT   DISULFID        358..408
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21047790"
FT   DISULFID        452..501
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        543..592
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         31..36
FT                   /note="Missing (in isoform 3, isoform 8, isoform 10 and
FT                   isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9872452"
FT                   /id="VSP_016424"
FT   VAR_SEQ         236
FT                   /note="T -> NHPYNDSSLRNHPDMYSA (in isoform 3, isoform 8 and
FT                   isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9872452"
FT                   /id="VSP_016425"
FT   VAR_SEQ         611..625
FT                   /note="Missing (in isoform 3, isoform 5, isoform 8 and
FT                   isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:15491607, ECO:0000303|PubMed:9872452"
FT                   /id="VSP_008937"
FT   VAR_SEQ         611..619
FT                   /note="ADQATPTNR -> GNCPCSPWH (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_016426"
FT   VAR_SEQ         620..1347
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_008938"
FT   VAR_SEQ         824..930
FT                   /note="Missing (in isoform 4, isoform 9 and isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_016427"
FT   VAR_SEQ         931
FT                   /note="V -> L (in isoform 4, isoform 9 and isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_016428"
FT   VAR_SEQ         1030..1203
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9872452"
FT                   /id="VSP_008940"
FT   VAR_SEQ         1030..1152
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_016430"
FT   VAR_SEQ         1030..1043
FT                   /note="ATPTAAPPTLPPTT -> GRCMAAAPGVKGPS (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15491607"
FT                   /id="VSP_016429"
FT   VAR_SEQ         1035..1203
FT                   /note="Missing (in isoform 8, isoform 10, isoform 11 and
FT                   isoform 12)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_016432"
FT   VAR_SEQ         1035..1113
FT                   /note="Missing (in isoform 13)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_016431"
FT   VAR_SEQ         1114..1203
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_016433"
FT   VAR_SEQ         1153
FT                   /note="S -> G (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_016434"
FT   VARIANT         159
FT                   /note="T -> M (in dbSNP:rs3795564)"
FT                   /id="VAR_017251"
FT   VARIANT         359
FT                   /note="R -> P (in NEDCPMD; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:28940097"
FT                   /id="VAR_083116"
FT   VARIANT         835..1347
FT                   /note="Missing (in NEDCPMD; no protein expression; unknown
FT                   pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:30124836"
FT                   /id="VAR_083117"
FT   VARIANT         1229
FT                   /note="V -> E (in NEDCPMD; decreased protein abundance in
FT                   patient-derived cells; decreased cell surface localization;
FT                   unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:30850329"
FT                   /id="VAR_083118"
FT   CONFLICT        807
FT                   /note="F -> L (in Ref. 3; BAB55195)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        972
FT                   /note="F -> V (in Ref. 3; AK127424)"
FT                   /evidence="ECO:0000305"
FT   STRAND          43..46
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          49..53
FT                   /evidence="ECO:0007829|PDB:3P40"
FT   STRAND          55..57
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          63..65
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          72..77
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   HELIX           84..86
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          94..96
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   TURN            104..106
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   HELIX           109..112
FT                   /evidence="ECO:0007829|PDB:3P40"
FT   STRAND          114..121
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          126..136
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          150..153
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          158..160
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          172..176
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          187..191
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          197..201
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   HELIX           205..207
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          211..216
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   TURN            218..220
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          223..225
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          231..234
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          236..238
FT                   /evidence="ECO:0007829|PDB:3P40"
FT   STRAND          246..249
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          251..259
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          264..267
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          277..282
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   TURN            289..291
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          292..295
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   HELIX           296..298
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          300..305
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   HELIX           308..310
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          312..319
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          324..341
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          346..348
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          354..357
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          359..364
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          367..372
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   HELIX           377..379
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          386..389
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          392..397
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          405..412
FT                   /evidence="ECO:0007829|PDB:3P3Y"
FT   STRAND          415..425
FT                   /evidence="ECO:0007829|PDB:3P3Y"
SQ   SEQUENCE   1347 AA;  150027 MW;  4DC555E5AA06C223 CRC64;
     MARQPPPPWV HAAFLLCLLS LGGAIEIPMD PSIQNELTQP PTITKQSAKD HIVDPRDNIL
     IECEAKGNPA PSFHWTRNSR FFNIAKDPRV SMRRRSGTLV IDFRSGGRPE EYEGEYQCFA
     RNKFGTALSN RIRLQVSKSP LWPKENLDPV VVQEGAPLTL QCNPPPGLPS PVIFWMSSSM
     EPITQDKRVS QGHNGDLYFS NVMLQDMQTD YSCNARFHFT HTIQQKNPFT LKVLTTRGVA
     ERTPSFMYPQ GTASSQMVLR GMDLLLECIA SGVPTPDIAW YKKGGDLPSD KAKFENFNKA
     LRITNVSEED SGEYFCLASN KMGSIRHTIS VRVKAAPYWL DEPKNLILAP GEDGRLVCRA
     NGNPKPTVQW MVNGEPLQSA PPNPNREVAG DTIIFRDTQI SSRAVYQCNT SNEHGYLLAN
     AFVSVLDVPP RMLSPRNQLI RVILYNRTRL DCPFFGSPIP TLRWFKNGQG SNLDGGNYHV
     YENGSLEIKM IRKEDQGIYT CVATNILGKA ENQVRLEVKD PTRIYRMPED QVARRGTTVQ
     LECRVKHDPS LKLTVSWLKD DEPLYIGNRM KKEDDSLTIF GVAERDQGSY TCVASTELDQ
     DLAKAYLTVL ADQATPTNRL AALPKGRPDR PRDLELTDLA ERSVRLTWIP GDANNSPITD
     YVVQFEEDQF QPGVWHDHSK YPGSVNSAVL RLSPYVNYQF RVIAINEVGS SHPSLPSERY
     RTSGAPPESN PGDVKGEGTR KNNMEITWTP MNATSAFGPN LRYIVKWRRR ETREAWNNVT
     VWGSRYVVGQ TPVYVPYEIR VQAENDFGKG PEPESVIGYS GEDYPRAAPT EVKVRVMNST
     AISLQWNRVY SDTVQGQLRE YRAYYWRESS LLKNLWVSQK RQQASFPGDR LRGVVSRLFP
     YSNYKLEMVV VNGRGDGPRS ETKEFTTPEG VPSAPRRFRV RQPNLETINL EWDHPEHPNG
     IMIGYTLKYV AFNGTKVGKQ IVENFSPNQT KFTVQRTDPV SRYRFTLSAR TQVGSGEAVT
     EESPAPPNEA TPTAAPPTLP PTTVGATGAV SSTDATAIAA TTEATTVPII PTVAPTTIAT
     TTTVATTTTT TAAATTTTES PPTTTSGTKI HESAPDEQSI WNVTVLPNSK WANITWKHNF
     GPGTDFVVEY IDSNHTKKTV PVKAQAQPIQ LTDLYPGMTY TLRVYSRDNE GISSTVITFM
     TSTAYTNNQA DIATQGWFIG LMCAIALLVL ILLIVCFIKR SRGGKYPVRE KKDVPLGPED
     PKEEDGSFDY SDEDNKPLQG SQTSLDGTIK QQESDDSLVD YGEGGEGQFN EDGSFIGQYT
     VKKDKEETEG NESSEATSPV NAIYSLA
//
